149 related articles for article (PubMed ID: 21571)
1. An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.
Mielke DH; Gallant DM; Kessler C
Am J Psychiatry; 1977 Dec; 134(12):1371-5. PubMed ID: 21571
[TBL] [Abstract][Full Text] [Related]
2. Sulpiride: evaluation of antipsychotic activity in schizophrenic patients.
Mielke DH; Gallant DM; Roniger JJ; Kessler C; Kessler LR
Dis Nerv Syst; 1977 Jul; 38(7):569-71. PubMed ID: 326504
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia.
Jeste DV; Neckers LM; Wagner RL; Wise CD; Staub RA; Rogol A; Potkin SG; Bridge TP; Wyatt RJ
J Clin Psychiatry; 1981 Feb; 42(2):75-7. PubMed ID: 6109719
[TBL] [Abstract][Full Text] [Related]
4. Sulpiride-induced tardive dystonia.
Miller LG; Jankovic J
Mov Disord; 1990; 5(1):83-4. PubMed ID: 1967484
[TBL] [Abstract][Full Text] [Related]
5. Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine.
Alfredsson G; Bjerkenstedt L; Edman G; Härnryd C; Oxenstierna G; Sedvall G; Wiesel FA
Acta Psychiatr Scand Suppl; 1984; 311():49-74. PubMed ID: 6199949
[TBL] [Abstract][Full Text] [Related]
6. A clinical and pharmacodynamic evaluation of sulpiride.
Rao VA; Bailey J; Bishop M; Coppen A
Psychopharmacology (Berl); 1981; 73(1):77-80. PubMed ID: 6785794
[TBL] [Abstract][Full Text] [Related]
7. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties.
Caley CF; Weber SS
Ann Pharmacother; 1995 Feb; 29(2):152-60. PubMed ID: 7756714
[TBL] [Abstract][Full Text] [Related]
8. Sulpiride--an antipsychotic agent: comparative trial vs. haloperidol.
Cassano GB; Castrogiovanni P; Conti L; Bonollo L
Psychopharmacol Bull; 1977 Jul; 13(3):41-3. PubMed ID: 18759
[No Abstract] [Full Text] [Related]
9. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
Kasper S
Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
[TBL] [Abstract][Full Text] [Related]
10. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
Csernansky JG; Kaplan J; Holman CA; Hollister LE
Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
[TBL] [Abstract][Full Text] [Related]
11. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced growth hormone and prolactin responses in schizophrenia research.
Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
[TBL] [Abstract][Full Text] [Related]
13. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
14. Amisulpride-induced tardive dyskinesia in childhood onset schizophrenia.
Goyal N; Sinha VK
Prog Neuropsychopharmacol Biol Psychiatry; 2010 May; 34(4):728-9. PubMed ID: 20347912
[No Abstract] [Full Text] [Related]
15. [Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride].
Liu KL; Lung FW
Kaohsiung J Med Sci; 1996 Dec; 12(12):685-90. PubMed ID: 9011126
[TBL] [Abstract][Full Text] [Related]
16. A risk-benefit assessment of sulpiride in the treatment of schizophrenia.
Mauri MC; Bravin S; Bitetto A; Rudelli R; Invernizzi G
Drug Saf; 1996 May; 14(5):288-98. PubMed ID: 8800626
[TBL] [Abstract][Full Text] [Related]
17. Tardive dystonia associated with low-dose of amisulpride: a case report.
Sevincok L; Balci V; Akyildiz U
J Clin Psychopharmacol; 2008 Oct; 28(5):573-4. PubMed ID: 18794659
[No Abstract] [Full Text] [Related]
18. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
19. Zuclopenthixol dihydrochloride for schizophrenia.
Kumar A; Strech D
Schizophr Bull; 2009 Sep; 35(5):855-6. PubMed ID: 19661197
[No Abstract] [Full Text] [Related]
20. Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms.
Naber D; Finkbeiner C; Fischer B; Zander KJ; Ackenheil M
Neuropsychobiology; 1980; 6(4):181-9. PubMed ID: 6104798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
